<DOC>
	<DOCNO>NCT03019835</DOCNO>
	<brief_summary>The antagonism neuromuscular block agent ( NMBA ) ( curare ) , well antagonism drug use anesthesia , major challenge speciality . Residual paralysis indeed risk factor post-operative morbidity mortality antagonization curare end procedure associate reduction mortality . Its use large possible contraindication extremely rare . The antagonism NMBA reduce duration neuromuscular block complication associate . In study , investigator use mivacurium ( Mivacron ) non-depolarizing curare neostigmine antagonist . Neostigmine reduce duration neuromuscular block induce mivacurium , By reduce breakdown acetylcholine , neostigmine induces increase acetylcholine synaptic cleft compete bind site nondepolarizing neuromuscular block agent , reverse neuromuscular blockade . But use neostigmine current practice widespread clinical situation . The reduction duration block significant comparison spontaneous recovery . Moreover , spontaneous recovery always complete sometimes long . Nevertheless , action effective study could support use also specify duration quality return normal neuromuscular transmission .</brief_summary>
	<brief_title>Can Antagonize Mivacurium With Neostigmine ?</brief_title>
	<detailed_description />
	<mesh_term>Paralysis</mesh_term>
	<mesh_term>Neostigmine</mesh_term>
	<mesh_term>Mivacurium</mesh_term>
	<criteria>Patients American Society Anesthesiologists ( ASA ) 1 3 Absence neuromuscular disease , renal hepatic insufficiency Absence medication could interfere mediator neuromuscular junction Bronchial asthma Parkinson disease BMI &gt; 35 Known hypersensitivity neostigmine excipients Neostigmine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>mivacurium</keyword>
	<keyword>neostigmine</keyword>
	<keyword>antagonism</keyword>
</DOC>